Clovis has confirmed a major victory with its ovarian cancer treatment Rubraca, the drug showing significant benefits for all patients in a maintenance setting – and better results than its rivals.

Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out. The FDA has ...